Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Karine Clément, Erica L T van den Akker, Jesús Argente, Allison Bahm, Hillori Connors, Kathleen De Waele, I. Sadaf Farooqi, Julie Gonneau-Lejeune, Gregory Gordon, Katja Kohlsdorf,

The Lancet Diabetes & Endocrinology · 2020 · 463 citations · 26 references

Concepts

References

26